NCT02151864: LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis |
|
|
| Completed | 1 | 9 | US | LDE225, hedgehog inhibitor | Jason K. Sicklick, M.D., Novartis Pharmaceuticals | Hepatocellular Carcinoma, Cirrhosis | 12/16 | 09/17 | | |
